Skip to main content
. 2016 Nov 21;4(4):27. doi: 10.3390/biomedicines4040027

Figure 5.

Figure 5

Innovative NMEs approved in 2011–2015. CDER used a number of regulatory methods including Fast Track, Breakthrough, Priority Review, and Accelerated Approval to expedite innovative NMEs to market.